Posts by: Daniela Semedo, PhD

Daniela Semedo, PhD

Daniela holds a PhD in Clinical Psychology from The University of Edinburgh, United Kingdom, a MSc in Health Psychology and a BSc in Clinical Psychology. Her work has been focused on vulnerability to psychopathology and early identification and intervention in psychosis.

July 2, 2015November 6, 2015

Study Presented at EULAR Shows Roche’s Esbriet Meets Safety Targets in Systemic Sclerosis-related Interstitial Lung Disease

News, Scleroderma

Results from a recent open-label trial presented during the European League Against Rheumatism Annual European Congress of Rheumatology showed that ESBRIET met its safety endpoint in the treatment of interstitial lung ... Read more

July 1, 2015November 5, 2015

Case Report Details Mycobacterium Tuberculosis in a Patient with Cystic Fibrosis

Cystic Fibrosis, News

In a recent case report published in the North American Journal of Medical Sciences, a team of researchers found that Mycobacterium tuberculosis (MTB) is an infrequent finding, but considered a ... Read more

June 30, 2015November 9, 2015

Invion Announces Complete Dosing in Phase II Study of Inv102 in Smoking Cessation For COPD Patients

COPD, News

Invion Limited, an Australian clinical-stage drug development company focused on the development of treatments for major market opportunities in inflammatory diseases including asthma, chronic bronchitis and lupus, recently announced the completion ... Read more

June 29, 2015November 9, 2015

Study Finds Association Between Heroin Inhalation and Early-onset COPD

COPD, News

Results from a recent study published in the Journal CHEST show that there is an association between heroin inhalation and early-onset COPD, particularly with an emphysema phenotype. For this study, ... Read more

June 25, 2015November 9, 2015

Mount Sinai Researchers Find That Annual LDCT Screening is Safe and Effective for Monitoring Patients With Non Solid Lung Nodules

COPD, News

According to a recent study published in the journal Radiology and conducted by a team of researchers from the Icahn School of Medicine at Mount Sinai (ISMMS), if patients with lung nodules ... Read more

June 19, 2015June 19, 2015

Batu Biologics Raises $1Million in Seed Funding to Target Lung Cancer

Lung Cancer, News

Batu Biologics, a immuno-oncology company focused on the development and commercialization of novel therapies that target the blood vessels of tumors, recently announced the completion of a seed funding round ... Read more

June 18, 2015November 5, 2015

UAB Researchers Find Acute Idiopathic Pulmonary Fibrosis Responds to Autoimmune Disease Therapy

Idiopathic Pulmonary Fibrosis, News

In a recent study published in the journal PLOS ONE, researchers from the University of Alabama at Birmingham demonstrated that patients with acute exacerbations of idiopathic pulmonary fibrosis (IPF) responded ... Read more

June 17, 2015June 17, 2015

Teva Announces FDA Acceptance of Reslizumab For Asthma

News

Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company, recently announced that the FDA has accepted reslizumab, the company’s investigational drug, for review for the Biologics License Application (BLA). The ... Read more

June 16, 2015September 16, 2015

Researchers Provide New Insights on Association Between Shorter Telomeres and Idiopathic Pulmonary Fibrosis

News

In a recent study published in the journal Respirology, a team of researchers found that shorter telomeres — which are the protective caps at the end of a cell’s chromosomes ... Read more

June 15, 2015November 5, 2015

Study Finds Triciribine Could Reverse Pulmonary Fibrosis and Pulmonary Hypertension Progression

Idiopathic Pulmonary Fibrosis, News

In a recent study published in the British Journal of Pharmacology, researchers at the University of Georgia found that the therapy triciribine could be able to reverse or stop pulmonary hypertension ... Read more